Pérez HJC, Padilla OJ

Language: Spanish
References: 31
Page: 125-130
PDF size: 104.17 Kb.

ABSTRACT

Methotrexate is a folic acid antagonist which reduces the levels of tetrahydrofolate in cells by inhibiting the enzyme dihydrofolate reductase and thymidylate synthetase responsibles for the synthesis of nucleic acids. This drug is used to treat inflammatory diseases such as rheumatoid arthritis. Myelosuppression, pancytopenia, agranulocytosis, mucosal necrosis among others are side effects and toxicity that may occur during the use of methotrexate. Toxicological severe cases associated with death are those with severe myelosuppression concomitant with infectious processes. This article reports a case of a patient who was treated with methotrexate and presents severe toxicity data, and concomitant infectious process. He is treated in the emergency department by toxicologists with favorable response, using hyperhydration, urine alkalinization, calcium folinate and colony stimulating factor.

REFERENCES

1. Moisa A, Fritz P, Benz D, Wehner HD. Iatrogenically-related, fatal methotrexate intoxication: a series of four cases. Forensic Sci Int 2006; 156: 154-157.

2. Seçkin Ü, Borman P, Bodur H, Han Ö, Gön B. Romatoid artritli bir olguda metotreksat tedavisini bağlı hızlanmış nodül gelişimi. Turk J Rheumatol 2000; 15: 137-140.

3. Alfaro J, Von Munlenbrock R, Burgos N et al. Intoxicación aguda con metotrexato usado con fines abortivos: descripción de dos casos. Rev Med Chil 2000; 128: 315-318.

4. Benedek TG. Methotrexate: from it’s introduction to non-oncologic there tics to anti-TNF. Clin Exp Rheumatol 2010; 28: S3-8.

5. Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 2011; 23 (3): 288-292.

6. Bleyer WA. The clinical pharmacology of methorexate: New applications of an old drug. Cancer 1978; 41: 36-51.

7. Hillson JL, Furst DE. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Rheum Dis Clin North Am 1993; 23: 757-778.

8. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 630-634.

9. Von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977; 61: 745-748.

10. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1993; 23: 739-755.

11. Del Pozo J, Martínez W, García-Silva J, Almagro M, Peña-Penabad C et al. Cutaneous ulceration as an sign of methotrexate toxicity. Eur J Dermatol 2001; 11: 450-452.

12. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991; 25: 306-318.

13. Kremer JM, Alarcón GS, Weinblatt ME, Kaymakcian MV, Macaluso M et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-1837.

14. Bartram SA. Experience with methotrexate-associated pneumonitis in northeastern England: comment on the article by Kremer et al. Arthritis Rheum 1998; 41: 1327-1328.

15. Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross WL. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 1996; 15: 277-282.

16. Zisman DA, McCune WJ, Tino G, Lynch JP 3rd. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 243-252.

17. Yang CP, Kuo MC, Guh JY, Chen HC. Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Renal Fail 2006; 20: 95-97.

18. Preet Singh Y, Aggarwal A, Misra R, Agarwal V. Low dose methotrexate-induced pancytopenia. Clin Rheumatol 2007; 26: 84-87.

19. Gaies E, Jebabli N, Trabelsi S, Salouage I, Charfi T et al. Methotrexate side effects: review article. J Drug Metab Toxicol 2012; 3: 125.

20. Bertino JR. Clinical pharmacology of methotrexate. Med Pediatr Oncol 1982; 10: 401-411.

21. Grimes DJ, Bowles MR, Buttsworth JA et al. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Sat 1990; 5: 447-454.

22. AACT/EAPCCT. Position statement: position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol 1999; 37: 731-751.

23. Christensen ML, Rivera GK, Crom WR, Hancock ML, Evans WE. Effect of hydration on metho- trexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 1988; 6: 797-801.

24. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19: 453-456.

25. Fox RM. Metotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 1979; 5: 43-44.

26. Kepka L, De Lassence A, Ribrag V et al. Successful rescue in a patient with high dose methotrexate-induced neprotoxicity and acute renal failure. Leuk Lynphoma 1998; 29: 205-209.

27. Gibbon BN, Manthey DE. Pediatric case of accidental overdose of oral methotrexate. Ann Emerg Med 1999; 34: 98-100.

28. Mackinnon SK, Starkebaum G, Willkens RF. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15: 119-126.

29. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G et al. Carboxipeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92: 480-487.

30. Gorostegui M, Martínez E, Llort A, Gros L, Dapena JL, Hidalgo E et al. Carboxipeptidasa G2 (CPDG2) en el rescate de la neurotoxicidad inducida por metotrexato a altas dosis (MTXHD). An Pediatr (Barc) 2007; 66: 434-446.

31. Steger J, Mader RM, Gnant MFX et al. GM-SCF in the treatment of a patient with severe methotrexate intoxication. J Intern Med 1993; 233: 499-502.